Evaluation of Antioxidant and Antitumor Activities of Wrightia arborea
Pages 625-632
Ronok Zahan, Laizuman Nahar, Ashik Mosaddik, Mohammad Abdur Rashid, Amir Hassan and Mansoor Ahmed

DOI: http://dx.doi.org/10.6000/1927-5129.2013.09.79

Published: 18 December 2013

Abstract: Wrightia arborea (Br.) (Family-Apocynaceae), locally known as Sathkurchi, is a small deciduous tree with small branches and densely velvety leaves. This study was designed to investigate the antioxidant and anti tumor activities of leaves of W. arborea.

Antioxidant potential was evaluated in vitro by DPPH (1,1-diphenyl-2-picrylhydrazyl) scavenging- and reducing power- assay method which was concentration dependent that was 25-200 µg/ml. The extract showed scavenging activity with IC₅₀ value of 15.23 ± 4.10 µg/ml for DPPH and also showed reducing activity in dose dependent manner. In addition, total phenol and flavonoid content were determined by Folin-Ciocalteu reagent and were found to be 112.54 ± 9.74 mg/g plant extract (in GAE) and 247.14 ± 15.45 mg/g plant extract (in quercetin equivalent), respectively. The antioxidant capacity was evaluated by phosphomolybdenum method and was found to be 117.27 ± 12.36 mg/g plant extract (in ascorbic acid equivalents). The anti tumor effect of the methanol extractwas determined with doses of 5, 10 and 20 mg/kg b.wt against Ehrlich ascites carcinoma (EAC) in mice with respect to the determination of tumor volume, tumor weight, % of cell growth inhibition, % increase in life span (%ILS), and hematological parameter (WBC, RBC and hemoglobin).

The methanol extract of W. arborea decreased the tumor weight significantly compared to control group at all the mentioned doses and the highest was observed at the dose of 20 mg/kg b. wt. (1.28 ± 0.15 g). The % of cell growth inhibition increased in dose dependent manner like 36.43 ± 7.45, 58.76 ± 9.43 and 98.43 ± 12.45 at the doses of 5, 10, 20 mg/kg b.wt. respectively. The %ILS was also enhanced in all the doses where 20 mg/kg b.wt showed maximum effect (105.5 ± 3.57). Heamoglobin (Hb) content was significantly increased 8.12 ± 2.6, 10.23 ± 1.62 and 12.12 ± 2.09 g/dL at the doses of 5, 10 and 20 mg/kg b.wt. respectively, compared to EAC control mice (4.95 ± 1.80 g). There was a significant (p< 0.05, p< 0.01, p<0.001) decrease in RBC count and increase in WBC counts in extract treated animals when compared to EAC control animals.

This is the first report of biological activities of leaves of W. arborea and it showed significant antioxidant as well as antitumor activity.

Development and Validation of a RP-HPLC Method for Simultaneous Determination of Levofloxacin and Moxifloxacin in Pharmaceutical Dosage Forms
Pages 633-638
Farjahan Nur, Asma Rahman, Md. Zakir Sultan, Md. Gias Uddin, Mohammad A. Rashid, Amir Hassan and Mansoor Ahmed

DOI: http://dx.doi.org/10.6000/1927-5129.2013.09.80

Published: 18 December 2013

Abstract: A simple, fast and economic reversed phase high performance liquid chromatographic (HPLC) method has been successfully developed and validated for simultaneous determination of fluoroquinolone analogs namely levofloxacin and moxifloxacin in both pure form (as API) and in pharmaceutical dosage forms. The method was validated according to the guidelines of ICH, FDA and USP with respect to accuracy, precision and linearity. For method development a C-18 bonded silica column (250 x 4.6 mm, 5μ, Phenomenex, Inc) was used with a mobile phase comprising of 10% aqueous solution of acetic acid and acetonitrile in a ratio of 80:20 v/v. The flow rate was 0.5 mL/min and effluents were monitored at 300 nm and the retention times were found to be at 7.0±0.1 min and 10.59±0.1 min for levofloxacin and moxifloxacin, respectively. The recovery was found to be more than 99% for each spiked samples of levofloxacin and moxifloxacin, demonstrating the accuracy of the protocol. Intra-day and inter-day precisions of the new method were less than the maximum allowable limit (RSD% £ 2.0) according to FDA. The method showed linear response with correlation coefficient value of 0.9975 in both the cases.

Therefore, the developed method was found to be simpler, accurate, reproducible, efficient and less time consuming and can be successfully applied for the simultaneous assay of levofloxacin and moxifloxacin formulations.